CN110897164A - 一种含有植物甾醇的组合物及其改善血糖的用途 - Google Patents
一种含有植物甾醇的组合物及其改善血糖的用途 Download PDFInfo
- Publication number
- CN110897164A CN110897164A CN201911333455.4A CN201911333455A CN110897164A CN 110897164 A CN110897164 A CN 110897164A CN 201911333455 A CN201911333455 A CN 201911333455A CN 110897164 A CN110897164 A CN 110897164A
- Authority
- CN
- China
- Prior art keywords
- composition
- amount
- functional food
- phytosterol
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 210000004369 blood Anatomy 0.000 title claims abstract description 24
- 239000008280 blood Substances 0.000 title claims abstract description 24
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000013376 functional food Nutrition 0.000 claims abstract description 19
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 15
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 15
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 12
- 240000008042 Zea mays Species 0.000 claims abstract description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 12
- 235000005822 corn Nutrition 0.000 claims abstract description 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 12
- 235000013557 nattō Nutrition 0.000 claims abstract description 12
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- 244000068988 Glycine max Species 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000007910 chewable tablet Substances 0.000 claims description 17
- 229940068682 chewable tablet Drugs 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 239000004376 Sucralose Substances 0.000 claims description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 9
- 235000019408 sucralose Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 7
- 239000000905 isomalt Substances 0.000 claims description 6
- 235000010439 isomalt Nutrition 0.000 claims description 6
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 229940068065 phytosterols Drugs 0.000 claims description 4
- 229960004580 glibenclamide Drugs 0.000 claims description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 6
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 description 5
- 235000002378 plant sterols Nutrition 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种含有植物甾醇的组合物及其用途。本申请提供一种组合物,其包含:植物甾醇、大豆肽、玉米低聚肽、磷脂、γ‑氨基丁酸和纳豆粉。本申请还涉及包含该组合物的功能食品和该组合物在制备用于改善血糖的功能食品中的用途。本申请提供的组合物和功能食品能够良好地调节和控制血糖水平。
Description
技术领域
本发明涉及一种含有植物甾醇的组合物及其用途,特别涉及一种含有植物甾醇的功能食品及其用途。
背景技术
糖尿病是由于胰岛素分泌及(或)作用缺陷引起的以血糖升高为特征的代谢病,长期血糖控制不佳的糖尿病患者,可伴发各种器官,尤其是眼、心、血管、肾、神经损伤或器官功能不全或衰竭,导致残废或者早亡。近40年来流行病学调查表明,我国糖尿病患病率一路飙升,根据2013年的调查,我国糖尿病的流行特点为:1)以2型糖尿病为主,1型及其他类型糖尿病少见。2型糖尿病患病率为10.4%,男性(11.1%)高于女性(9.6%)。2)经济发达地区的患病率明显高于不发达地区,城市(12.0%)高于农村(8.9%)。3)未诊断糖尿病比例较高,占患病综述的63%。4)肥胖和超重人群糖尿病患病率显著增加,肥胖人群糖尿病患病率升高了2倍。糖尿病患者常合并一个或多个代谢综合征的临床表现,如高血压、血脂异常、肥胖等疾病,这些伴随疾病增加了糖尿病并发症的发生风险、发展速度及危害。2型糖尿病的防治必须采取多种疾病同时干预的综合防治措施。目前,糖尿病的综合控制目标包括将血糖、血压、血脂、体质指数在内的多项指标控制在目标值范围内,以减少微血管或大血管并发症的发生。
发明内容
为了实现上述目的,本申请提供一种组合物,其包含:植物甾醇、大豆肽、玉米低聚肽、磷脂、γ-氨基丁酸和纳豆粉。在一些实施例中,本申请的组合物还包含:异麦芽酮糖醇、甘露糖醇、微晶纤维素、炒麦芽、硬脂酸镁和三氯蔗糖。在一些实施例中,基于本申请组合物的总重量,植物甾醇的量为16%~25%,大豆肽的量为1%~10%,玉米低聚肽的量为1%~10%,磷脂的量为1%~10%,γ-氨基丁酸的量为1%~5%,纳豆粉的量为1%~5%。
在另一方面,本申请还涉及一种功能食品,其包含本申请中所述的组合物。在一些实施例中,功能食品是片剂形式,例如为咀嚼片。
在另一方面,本申请还涉及上述组合物在制备用于改善血糖的功能食品中的用途。
植物甾醇是中国、欧洲、美国等多个国家以及ESC/EAS等医学协会指南和共识均推荐血脂异常人群食用以帮助降低血脂和预防心血管疾病,推荐剂量为2~3g/天。但是,目前并未报道将植物甾醇用于调节血糖的功能食品。本发明的申请人出人意料地发现,本申请提供的特定组成的组合物不仅仅能够用于降低血脂,还能够用于调节血糖水平;并且,即使在低剂量植物甾醇的情况下也能够实现对血糖水平的调节和改善。
具体实施方式
本申请的第一方面提供一种组合物,其包含:植物甾醇、大豆肽、玉米低聚肽、磷脂、γ-氨基丁酸和纳豆粉。
在一些实施例中,基于本申请咀嚼片的总重量,植物甾醇的含量为16%~25%,优选为17%~24%,更优选为18%~22%。例如,植物甾醇的含量可以为16%、17%、18%、19%、19.5%、20%、20.5%、21%、21.5%、22%、23%、24%、25%或上述数值之间的任意范围。
在一些实施例中,基于本申请咀嚼片的总重量,大豆肽、玉米低聚肽和磷脂的含量各自为1%~10%,优选为3%~7%,更优选为4%~6%。例如,大豆肽、玉米低聚肽和磷脂的含量各自可以为约1%、2%、3%、4%、5%、6%、7%、8%、9%、10%或上述数值之间的任意范围。
在一些实施例中,基于本申请咀嚼片的总重量,γ-氨基丁酸和纳豆粉的含量各自为1%~5%,优选为1%~3%,更优选为1%~2%。例如,γ-氨基丁酸和纳豆粉的含量各自可以为约1.0、1.25%、1.5%、2.0%、3.0%、4.0%、5.0%或上述数值之间的任意范围。
植物甾醇,与胆固醇具有相似的结构,能够通过在消化道内与胆固醇竞争吸收位点、抑制胆固醇转运蛋白基因表达和减少胆固醇再酯化等方式能够减少30%~50%的饮食中胆固醇吸收,此外植物甾醇还能够提高体内胆固醇的清除,具有降低血清胆固醇和低密度脂蛋白胆固醇水平的作用。
植物低聚肽是指来源于可食用植物蛋白,分子结构介于氨基酸和蛋白质之间的一类化合物。植物低聚肽相比蛋白质,溶解性增强,吸收更好。具有免疫调节、抗氧化、调节血压和抑制肿瘤生长等多种生理活性。在一些实施例中,植物低聚肽选自大豆肽和玉米低聚肽中的至少一种。
γ-氨基丁酸是一种广泛分布在动植物体内的活性物质,是大脑中最重要的神经递质之一,具有神经营养、抗焦虑、促进血管扩张和参与镇痛的作用。
磷脂具有亲水、亲油的乳化作用,能参与脂肪和胆固醇的运输,降低血清胆固醇、甘油三酯、低密度脂蛋白胆固醇。纳豆中富含纳豆激酶,是一种天然的溶纤酶,具有溶栓的作用。
在一些实施例中,本申请的组合物还包含:异麦芽酮糖醇、D-甘露糖醇、微晶纤维素、炒麦芽、硬脂酸镁和三氯蔗糖。
在一些实施例中,基于本申请咀嚼片的总重量,异麦芽酮糖醇、微晶纤维素和D-甘露糖醇的含量各自为16%~28%,优选为16%~24%,更优选为18%~22%。例如,植物甾醇的含量可以为16%、17%、18%、19%、19.5%、20%、20.5%、21%、21.5%、22%、23%、24%、25%、26%、27%、28%或上述数值之间的任意范围。
在一些实施例中,基于本申请咀嚼片的总重量,炒麦芽的含量为1%~5%,优选为1%~3%,更优选为1%~2%。
在一些实施例中,基于本申请组合物的总重量,硬脂酸镁的含量为1%~6%,优选为1%~4%,更优选为1%~3%。
在一些实施例中,基于本申请组合物的总重量,三氯蔗糖的含量为0.01%~0.08%,优选为0.02%~0.07%,更优选为0.03%~0.06%。例如,三氯蔗糖的含量为约0.02%、0.04%、0.05%或为上述数值之间的任意范围。
在一些实施例中,本申请的组合物由以下成分组成:植物甾醇,大豆肽,磷脂、玉米低聚肽、γ-氨基丁酸、纳豆粉、异麦芽酮糖醇、D-甘露糖醇、微晶纤维素、炒麦芽粉、硬脂酸镁和三氯蔗糖。优选地,该实施例中各个组份的含量为上述所描述的任意含量。
本申请的另一方面涉及一种功能食品,其包含本申请中所述的任一种组合物。在一些实施例中,本申请的功能食品可以为胶囊、片剂、丸剂、颗粒剂中的任意一种,优选为片剂,更优选为咀嚼片。本申请的发明人出人意料地发现,本申请中所描述的功能食品可以显著地改善食用者的血糖。
本申请的另一方面涉及上述组合物用于制备改善血糖的功能食品中的用途。
本发明的有益之处在于,相比其他改善功能性食品,本发明提供的含有植物甾醇的功能食品使食用者的血糖、血脂和血压得到均衡的改善和综合的控制,能够对糖尿病起到良好的防治作用。
实施例
下面结合实施例对本发明作进一步详细的描述,但本发明的实施方式不限于此。
实施例1:植物甾醇复合营养素颗粒
植物甾醇20%,大豆肽5%,磷脂5%、玉米低聚肽4%、γ-氨基丁酸1.25%、纳豆粉1.5%、异麦芽酮糖醇20%、D-甘露糖醇20%、微晶纤维素20%、炒麦芽粉1.2%、硬脂酸镁2%、三氯蔗糖0.05%
1):所有原辅料分别过60目筛。
2):将过筛后的植物甾醇、大豆肽、磷脂、玉米低聚肽、γ-氨基丁酸、D-甘露糖醇、微晶纤维素、异麦芽酮糖醇、炒麦芽粉、纳豆粉、硬脂酸镁、三氯蔗糖置于湿法制粒机中混合均匀,以水为粘合剂制粒。
3):用沸腾干燥机烘干,先烘半干,再用16目筛制粒。
4):制好的半干颗粒再用沸腾干燥机烘干,水分控制在4.0%~4.5%左右,再用20目筛整粒即得。
实施例2:植物甾醇复合营养素咀嚼片人群服用1
63岁女性,服用植物甾醇复合营养素咀嚼片,剂量以植物甾醇计,960mg/天,持续45天。血糖、血脂指标均改善,患者自述口渴症状明显减轻。
实施例3:植物甾醇复合营养素咀嚼片人群服用2
43岁男性,口服格列本脲片5.0mg/天,服用植物甾醇复合营养素咀嚼片,剂量以植物甾醇计,960mg/天,持续45天。血糖指标明显改善,口渴症状缓解,精力改善,格列本脲片剂量降为2.5mg/天。
实施例4:植物甾醇复合营养素咀嚼片血脂异常人群试服个体数据32岁男性,植物甾醇复合营养素咀嚼片,剂量以植物甾醇计,480mg/天,持续6周。
实施例5:植物甾醇复合营养素咀嚼片血脂异常人群试服个体数据72岁女性,植物甾醇复合营养素咀嚼片,剂量以植物甾醇计,960mg/天,持续8周。
实施例6:植物甾醇复合营养素咀嚼片血脂异常人群试服个体数据58女性,植物甾醇复合营养素咀嚼片,剂量以植物甾醇计,前8周960mg/天,后四周480mg/天,共持续12周。
根据上述实施例可以看出,本申请的植物甾醇组合物能够在低剂量的水平下用于调控血脂指标,并且同时能够出人意料地改善血糖水平。
本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (9)
1.一种组合物,其包含:植物甾醇、大豆肽、玉米低聚肽、磷脂、γ-氨基丁酸和纳豆粉。
2.根据权利要求1所述的组合物,其还包含:异麦芽酮糖醇、D-甘露糖醇、微晶纤维素、炒麦芽、硬脂酸镁和三氯蔗糖。
3.根据权利要求1-2中任一项所述的组合物,其中,基于所述组合物的总重量,植物甾醇的量为16%~25%,大豆肽的量为1%~10%,玉米低聚肽的量为1%~10%,磷脂的量为1%~10%,γ-氨基丁酸的量为1%~5%,纳豆粉的量为1%~5%。
4.根据权利要求2中任一项所述的组合物,其中,基于所述组合物的总重量,所述异麦芽酮糖醇的量为16%~28%,所述D-甘露糖醇的量为16%~28%,所述微晶纤维素的量为16%~28%,所述炒麦芽的量为1%~5%、所述硬脂酸镁的量为1%~6%,所述三氯蔗糖的量为0.01%~0.08%。
5.根据权利要求1-4中任一项所述的组合物在制备用于改善血糖的功能食品中的用途。
6.根据权利要求5所述的用途,其中所述功能食品与格列本脲片组合食用。
7.一种功能食品,其包含根据权利要求1-4中任一项所述的组合物。
8.根据权利要求6所述的功能食品,其为胶囊、片剂、丸剂、颗粒剂中的任意一种。
9.根据权利要求6所述的功能食品,所述功能食品为咀嚼片的形式。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911333455.4A CN110897164A (zh) | 2019-12-26 | 2019-12-26 | 一种含有植物甾醇的组合物及其改善血糖的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911333455.4A CN110897164A (zh) | 2019-12-26 | 2019-12-26 | 一种含有植物甾醇的组合物及其改善血糖的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110897164A true CN110897164A (zh) | 2020-03-24 |
Family
ID=69827094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911333455.4A Pending CN110897164A (zh) | 2019-12-26 | 2019-12-26 | 一种含有植物甾醇的组合物及其改善血糖的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110897164A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1617670A (zh) * | 2001-12-21 | 2005-05-18 | 拉伊西奥比尼考有限公司 | 用于改善血清脂类分布和预防动脉粥样硬化的含水解蛋白质和植物甾醇的组合物 |
CN102885306A (zh) * | 2012-10-12 | 2013-01-23 | 中科乐仁(北京)科技发展有限公司 | 一种辅助降血脂的保健食品组合物及其制备方法 |
CN103230478A (zh) * | 2013-05-02 | 2013-08-07 | 广州施健生物科技有限公司 | 一种富硒纳豆制品 |
CN105747235A (zh) * | 2016-03-04 | 2016-07-13 | 通泰心脑健康管理有限公司 | 一种能改善代谢综合征症状的饮食组合物 |
CN106617072A (zh) * | 2016-12-20 | 2017-05-10 | 广州莱可福生物科技有限公司 | 一种植物甾醇复合降脂组方及其片剂制备方法 |
CN108347988A (zh) * | 2015-09-03 | 2018-07-31 | 以色列2016天然防护有限公司 | 用于控制血糖水平、护肝以及用于预防和治疗相关医学病症的组合的组合物 |
CN111035620A (zh) * | 2019-12-25 | 2020-04-21 | 广州莱可福生物科技有限公司 | 一种辅料组合物、植物甾醇复合营养素咀嚼片及其制备方法 |
-
2019
- 2019-12-26 CN CN201911333455.4A patent/CN110897164A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1617670A (zh) * | 2001-12-21 | 2005-05-18 | 拉伊西奥比尼考有限公司 | 用于改善血清脂类分布和预防动脉粥样硬化的含水解蛋白质和植物甾醇的组合物 |
CN102885306A (zh) * | 2012-10-12 | 2013-01-23 | 中科乐仁(北京)科技发展有限公司 | 一种辅助降血脂的保健食品组合物及其制备方法 |
CN103230478A (zh) * | 2013-05-02 | 2013-08-07 | 广州施健生物科技有限公司 | 一种富硒纳豆制品 |
CN108347988A (zh) * | 2015-09-03 | 2018-07-31 | 以色列2016天然防护有限公司 | 用于控制血糖水平、护肝以及用于预防和治疗相关医学病症的组合的组合物 |
CN105747235A (zh) * | 2016-03-04 | 2016-07-13 | 通泰心脑健康管理有限公司 | 一种能改善代谢综合征症状的饮食组合物 |
CN106617072A (zh) * | 2016-12-20 | 2017-05-10 | 广州莱可福生物科技有限公司 | 一种植物甾醇复合降脂组方及其片剂制备方法 |
CN111035620A (zh) * | 2019-12-25 | 2020-04-21 | 广州莱可福生物科技有限公司 | 一种辅料组合物、植物甾醇复合营养素咀嚼片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6652891B2 (en) | Co-enzyme Q10 dietary supplement | |
KR100591045B1 (ko) | 당뇨병용 조성물 | |
EP2011500A1 (en) | Fat accumulation inhibitor | |
JP2008174539A (ja) | 紫色の馬鈴薯を使用した肥満患者用の健康機能食品 | |
KR20170028486A (ko) | 꽃송이버섯 및 유산균을 유효성분으로 포함하는 갱년기 또는 폐경기 증상의 예방, 치료 또는 개선용 조성물 | |
CN107613998A (zh) | 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 | |
CN107223981B (zh) | 含大豆多肽阿格拉欣的组合物及其制备方法 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
JP2024072583A (ja) | Gabaを有効成分とする乳腺組織の健康維持剤 | |
CN110897164A (zh) | 一种含有植物甾醇的组合物及其改善血糖的用途 | |
WO2016124080A1 (zh) | 20(R)-人参皂苷Rg3在制备预防或/和治疗肥胖症药物中的应用及药物 | |
CN103768098B (zh) | 一种鹿角胶的制备方法及其应用 | |
KR101626642B1 (ko) | 당뇨병 개선 효과능이 있는 탱자 발효 조성물 | |
KR102239066B1 (ko) | 식물 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
CN111035620B (zh) | 一种辅料组合物、植物甾醇复合营养素咀嚼片及其制备方法 | |
TWI776450B (zh) | 正丁基苯酞於促進脂肪褐變、以及預防或治療脂肪肝及相關肝病變之應用 | |
KR100959281B1 (ko) | 혈당강하 효능을 갖는 칼슘 화합물 시비 쌀 | |
KR20170012169A (ko) | 경구용 복합제제 | |
KR20220118504A (ko) | 비만 억제용 조성물 | |
KR101811210B1 (ko) | 마가목 열매 추출물을 유효성분으로 하는 당뇨 질환 치료, 개선 또는 예방용 조성물 | |
JP3476835B2 (ja) | ヤーコン・ウーロン配合食品 | |
CN111011850A (zh) | 一种含有植物甾醇的组合物的用途 | |
KR102507569B1 (ko) | 돌외잎 추출물의 제조방법 및 이에 따른 돌외잎 추출물 | |
KR20190043415A (ko) | 생약 혼합물을 유효성분으로 포함하는 항비만 조성물 | |
CN108244643B (zh) | 一种可管控体重和提升运动能力的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200324 |
|
RJ01 | Rejection of invention patent application after publication |